Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

PureTech (PRTC) Share Price

Price 132.60p on 20-04-2026 at 18:50:08
Change 0.20p 0.15%
Buy 133.20p
Sell 130.00p
Last Trade: Unknown 1,651.00 at 134.29158p
Day's Volume: 470,359
Last Close: 132.60p
Open: 132.00p
ISIN: GB00BY2Z0H74
Day's Range 129.80p - 134.20p
52wk Range: 104.80p - 148.00p
Market Capitalisation: £322.77m
VWAP: 132.44239p
Shares in Issue: 243.42m

PureTech (PRTC) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 1,651 134.29158p Currency Conversion
Negotiated Trade
16:39:57 - 20-Apr-26
Sell* 530 132.60p SI Trade
16:35:04 - 20-Apr-26
Sell* 1,584 132.60p SI Trade
16:35:04 - 20-Apr-26
Sell* 128,375 132.60p Uncrossing Trade
16:35:04 - 20-Apr-26
Sell* 185 132.80p Automatic Execution
16:28:42 - 20-Apr-26
Sell* 263 132.80p Automatic Execution
16:27:00 - 20-Apr-26
Sell* 361 132.80p Automatic Execution
16:27:00 - 20-Apr-26
Buy* 236 133.00p Automatic Execution
16:18:56 - 20-Apr-26
Buy* 735 133.00p Automatic Execution
16:18:56 - 20-Apr-26
Sell* 1,961 132.80p Automatic Execution
16:16:37 - 20-Apr-26
See more PureTech trades

PureTech (PRTC) Share Price History

Time period:
to
Date Open High Low Close Volume
20th Apr 2026 (Mon) 132.00 134.20 129.80 132.60 470,359
17th Apr 2026 (Fri) 132.00 133.00 130.80 132.40 450,134
16th Apr 2026 (Thu) 128.00 135.00 128.00 131.60 412,008
15th Apr 2026 (Wed) 130.00 134.00 130.00 133.40 501,260
14th Apr 2026 (Tue) 127.20 133.60 127.20 131.40 1,239,841
13th Apr 2026 (Mon) 127.00 132.40 126.60 130.20 1,681,260
10th Apr 2026 (Fri) 119.80 122.20 119.80 121.40 797,931
9th Apr 2026 (Thu) 122.00 122.00 117.40 118.60 239,028
8th Apr 2026 (Wed) 116.80 119.60 116.00 119.60 2,715,069
7th Apr 2026 (Tue) 115.00 115.40 112.40 113.60 1,180,402
6th Apr 2026 (Mon) 113.00 113.00 113.00 113.00 0
3rd Apr 2026 (Fri) 113.00 113.00 113.00 113.00 0
2nd Apr 2026 (Thu) 108.00 114.00 107.60 113.00 2,435,373
1st Apr 2026 (Wed) 113.00 113.00 109.40 110.00 1,277,081
31st Mar 2026 (Tue) 107.80 109.20 107.40 108.00 940,746
30th Mar 2026 (Mon) 116.20 116.20 108.00 108.00 799,681
27th Mar 2026 (Fri) 118.20 118.20 110.00 110.00 686,172
26th Mar 2026 (Thu) 115.00 115.60 113.40 114.60 293,260
25th Mar 2026 (Wed) 120.00 120.00 114.00 115.00 299,041
24th Mar 2026 (Tue) 114.00 115.20 112.40 114.20 235,278
23rd Mar 2026 (Mon) 116.00 117.40 110.80 114.00 440,265
See more PureTech price history

PureTech (PRTC) Regulatory News

Date Source Headline
16th Apr 2026 5:00 pm RNS Holding(s) in Company
16th Apr 2026 7:00 am RNS Holding(s) in Company
13th Apr 2026 7:05 am RNS Notice of Results
13th Apr 2026 7:00 am RNS PRTC's Seaport Files for Proposed Nasdaq IPO
1st Apr 2026 7:00 am RNS Total Voting Rights
25th Mar 2026 6:00 pm RNS-R PRTC’s Seaport: GlyphAllo Paper Published
13th Mar 2026 4:35 pm RNS PDMR Notification RSU Vesting
2nd Mar 2026 7:00 am RNS Total Voting Rights
25th Feb 2026 7:00 am RNS-R PRTC to Present at Leerink Healthcare Conference
19th Feb 2026 5:15 pm RNS-R PRTC's Deupirfenidone Granted FDA & EU ODD for IPF
See more PureTech regulatory news

PureTech (PRTC) Share News

PureTech Health's Seaport files for possible Nasdaq listing

13th Apr 2026 10:49

(Alliance News) - PureTech Health PLC on Monday said that Seaport Therapeutics Inc, founded by PureTech, had filed for an initial public offering on New York's Nasdaq Stock Market. Read More

EARNINGS AND TRADING: McBride proposes cash acquisition of Eurotab

2nd Apr 2026 17:50

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

PureTech says its pulmonary fibrosis drug granted orphan designation

20th Feb 2026 13:11

(Alliance News) - PureTech Health PLC said on Friday its drug treating idiopathic pulmonary fibrosis, deupirfenidone, has been designated as an orphan drug by both the US Food & Drug Administration and the European Commission. Read More

IN BRIEF: PureTech Health promotes interim CEO Robert Lyne to CEO

18th Dec 2025 11:11

PureTech Health PLC - Boston, Massachusetts-based biotech and pharmaceutical firm - Promotes interim Chief Executive Officer Robert Lyne to CEO on a permanent basis from Thursday. Lyne has served as interim CEO since July, having joined the company in January 2024 as chief portfolio officer. He has overseen progress across PureTech's programmes and advancing strategic and operational priorities. Lyne was previously CEO of Arix Bioscience PLC. Read More

FDA backs PureTech's phase 3 move for IPF drug deupirfenidone

8th Dec 2025 12:34

(Alliance News) - PureTech Health PLC on Monday said its idiopathic pulmonary fibrosis drug candidate deupirfenidone has cleared a key regulatory milestone, with the US Food & Drug Administration backing progression into a pivotal phase 3 trial planned for the first half of 2026. Read More

See more PureTech news
FTSE 100 Latest
Value10,609.08
Change-58.55

Login to your account

Forgot Password?

Not Registered